BG
CDTX

BlackRock Group’s Cidara Therapeutics CDTX Stock Holding History

BlackRock Group’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,469
Closed -$374K – 3009
2015
Q3 		$374K Hold
1,469
– – ﹤0.01% 2313
2015
Q2 		$412K Buy
+1,469
New +$452K ﹤0.01% 2334

Other funds holding CDTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock Group's CDTX Position: Q4 2015 in Review

BlackRock Group sold out of Cidara Therapeutics (CDTX) in Q4 2015, closing a stake of 1,469 shares — an estimated $374K sold.

BlackRock Group first reported a position in CDTX in Q2 2015 and held it in 2 quarters. The position peaked at $412K in Q2 2015. 46 funds tracked by Wall St. Rank hold CDTX as of Q4 2015.

  • BlackRock Group reported no remaining Cidara Therapeutics position as of Q4 2015 after selling out during the quarter.
  • BlackRock Group sold 1,469 Cidara Therapeutics shares in Q4 2015, an estimated $374K.
  • BlackRock Group first reported a position in Cidara Therapeutics in Q2 2015 and held it in 2 quarters.
  • BlackRock Group's Cidara Therapeutics position peaked at $412K in Q2 2015.
  • 46 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2015.

Based on BlackRock Group's 13F filing for Q4 2015, filed 11 Feb 2016.